SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review
9 references·0 citing·37 second hop
Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review (2018)Evaluation of the quality of the reportin…Quality of reporting of phase II trials: a focus on highly ranked oncology journals (2014)Quality of reporting of phase…CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (2010)CONSORT 2010 Statement: updat…Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group (2004)Bad reporting does not mean b…The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials (2001)The CONSORT statement: revise…Improving the Quality of Reporting of Randomized Controlled Trials (1996)Improving the Quality of Repo…Improving the Quality of Reporting of Randomized Controlled Trials (1996)Improving the Quality of Repo…A Handbook of Test Construction: Introduction to Psychometric Design (1987)A Handbook of Test Constructi…Health Measurement Scales: A Practical Guide to Their Development and Use (1989)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting (2000)The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)Cochrane Handbook for Systematic Reviews of Interventions (2008)The price of innovation: new estimates of drug development costs (2003)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Clinical development success rates for investigational drugs (2014)Cost of innovation in the pharmaceutical industry (1991)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Incentives for orphan drug research and development in the United States (2008)The High Cost of Cancer Drugs and What We Can Do About It (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide (2014)Standards for Reporting Qualitative Research (2014)Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation (2015)Empirical Evidence of Bias (1995)Empirical Evidence of Bias (1995)Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? (1998)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration (2009)The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)Systematic Reviews: Identifying relevant studies for systematic reviews (1994)CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010)CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials (2010)SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials (2013)Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review (2017)Adherence to reporting guidelines and clinical trial registration policies in oncology journals: a cross-sectional review (2018)An Integrative Model Of Organizational Trust (1995)Constructing validity: Basic issues in objective scale development. (1995)An Integrative Model of Organizational Trust: Past, Present, and Future (2007)Core outcome domains for chronic pain clinical trials: IMMPACT recommendations (2003)Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007)
this work references cited by second hop

References

  • 2010CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials13,387 cited
  • 2004Can the pharmaceutical industry reduce attrition rates?4,230 cited
  • 1996Improving the Quality of Reporting of Randomized Controlled Trials4,099 cited
  • 1996Improving the Quality of Reporting of Randomized Controlled Trials3,126 cited
  • 2001The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials2,754 cited
  • 1987A Handbook of Test Construction: Introduction to Psychometric Design625 cited
  • 2007Economics of New Oncology Drug Development348 cited
  • 2004Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group318 cited
  • 2014Quality of reporting of phase II trials: a focus on highly ranked oncology journals19 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work